Good results. Brain degeneration and dementia and Alzheimer’s must be the next holy grail for medicine. FDA starting to be more receptive to clinical trials and CGS will be in the middle of all this activity. Revenue from operations up 66%.
CGS are about to release their IP on smartphones in Asia that allows the phone to detect cognitive decline in the user and report back!
"We expect revenue delays, which are timing issues only, to continue into 2Q23 but to largely recover in 2H23."
Income deferred. Is that such a problem?
